脉络舒通丸联合利伐沙班治疗下肢深静脉血栓形成后综合征的临床效果

Clinical effect of Mailuo Shutong Pills combined with rivaroxaban in treatment of sequelae of lower extremity venous thrombosis

摘要:

目的 探讨脉络舒通丸联合利伐沙班治疗下肢深静脉血栓形成后综合征(PTS)的临床效果。方法 回顾性分析2019年6月至2020年9月潍坊市人民医院血管外科收治的60例下肢深静脉血栓形成后综合征患者的临床资料。根据治疗方法不同将患者分为对照组和观察组,各30例。对照组患者给予利伐沙班片、弹力袜等基础治疗措施,观察组患者在对照组治疗方法的基础上,给予口服脉络舒通丸。记录患者Villalta评分和血液中纤维蛋白原含量(FIB)、活化部分凝血活酶时间(APTT)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)等指标及不良反应发生情况。采用SPSS 22.0统计软件进行数据分析。根据数据类型,分别采用t检验、χ²检验或Fisher精确检验进行组间比较。结果 治疗后观察组Villalta评分(包括患肢肿胀、疼痛、色素沉着等)明显优于对照组[(6.17±2.20)和(7.43±1.50)分]；炎症指标(IL-6、hs-CRP)与FIB水平明显低于对照组[(32.35±4.68)和(48.75±5.21)pg/ml,(13.51±3.89)和(18.87±4.28)mg/L,(2.43±0.41)和(2.79±0.47)g/L],差异均有统计学意义(P＜0.05)。2组患者APTT及不良反应发生情况比较,差异均无统计学意义(P＞0.05)。结论 脉络舒通丸联用利伐沙班可显著提升PTS的治疗效果,改善患者凝血功能和炎症反应情况,且安全性较好。

Abstract:

Objective To explore the clinical effect of Mailuo Shutong Pills combined with rivaroxaban in the treatment of post-deep vein thrombosis syndrome of lower extremity. Methods A retrospective study was conducted of the clinical data of 60 patients with sequelae of lower extremity deep venous thrombosis treated in the Department of Vascular Surgery of Weifang People′s Hospital from June 2019 to September 2020. According to the treatment regimen, they were divided into control group (n=30) and study group (n=30). The control group received basic treatment such as rivaroxaban tablets and elastic stockings, and the study group were treated with additional Mailuo Shutong Pills. The Villalta score, fibrinogen (FIB), activated partial thromboplastin time (APTT), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) were recorded. SPSS statistics 22.0 was used for data analysis. According to the data type, t-test, χ² test, or Fisher′s exact test was used for comparison between groups. Results After treatment, the study group had significantly better Villalta score (including swelling, pain and pigmentation of the affected extremity), lower inflammatory indexes (IL-6 and hs-CRP) and FIB than the control group [(6.17±2.20)vs (7.43±1.50) points, (32.35±4.68)vs(48.75±5.21)pg/ml, (13.51±3.89) vs (18.87±4.28) mg/L, (2.43±0.41)vs (2.79±0.47)g/L, P<0.05]. There were no significant differences in APTT and adverse reactions between the two groups (P>0.05). Conclusion Mailuo Shutong Pills combined with rivasaban can significantly enhance the therapeutic efficacy in PTS, improving blood coagulation and inflammatory reaction with good safety.